SCHEMBL5805189

SCHEMBL5805189

CC1=NN(c2ccc(Br)cc2)C(c2ccccc2)C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.64
▸ ALDH1A1 P00352 4/20 0.64
▸ HTT P42858 1/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ CA1 P00915 2/20 0.53
▸ CA2 P00918 2/20 0.53
▸ PRKCZ Q05513 2/20 0.50
▸ PDE5A O76074 2/20 0.49
▸ RIPK1 Q13546 1/20 0.48
▸ EGFR P00533 1/20 0.47
▸ ERBB2 P04626 1/20 0.47
▸ MEN1 O00255 5/20 0.45
▸ KMT2A Q03164 5/20 0.45
▸ L3MBTL1 Q9Y468 3/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ GAA P10253 2/20 0.45
▸ ATM Q13315 2/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ GLA P06280 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8103392 0.89 MAPT (0.68) MAPTALDH1A1HTTSMN1; SMN2CA1
SCHEMBL31429970 0.77 EGFR (0.74) MAPTALDH1A1HTTCA1CA2
SCHEMBL31429952 0.76 SMN1; SMN2 (0.61) MAPTALDH1A1HTTSMN1; SMN2CA1
SCHEMBL5802366 0.76 MAPT (0.57) MAPTALDH1A1HTTSMN1; SMN2CA1
SCHEMBL23269369 0.75 BCL2 (0.64) RIPK1MEN1KMT2AATM
SCHEMBL6294114 0.75 CA1 (0.56) MAPTALDH1A1HTTSMN1; SMN2CA1
SCHEMBL2687295 0.74 EGFR (0.78) MAPTALDH1A1HTTCA1CA2
SCHEMBL22796281 0.74 ESD (0.53) MAPTALDH1A1HTTSMN1; SMN2RIPK1
SCHEMBL5052866 0.74 MAPT (0.55) MAPTALDH1A1HTTSMN1; SMN2PDE5A
SCHEMBL5693269 0.74 MAPT (0.59) MAPTALDH1A1HTTSMN1; SMN2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1385524-A4 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2006-02-01 — — EP disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
CN-1520298-A Pyrazolopyrimidines as therapeutic agents �����ʩ���عɷݹ�˾ 2004-08-11 — — CN disclosed
EP-1212327-B8 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2004-02-25 — — EP disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 — — EP disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
CN-1390219-A Pyrazolopyrimidines as therapeutic agents ABBOTT AG (DE) 2003-01-08 — — CN disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 — — WO disclosed
EP-1212327-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2002-06-12 — — EP disclosed
WO-2001019829-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2001-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 MAPT 3263/4885ALDH1A1 99/4885HTT 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback